The answer depends on the concentration in your vial
After a median follow-up of 104 weeks, treatment with tirzepatide was associated with a significant reduction in the risk of adjudicated death from cardiovascular causes or a worsening heart failure event (hazard ratio (HR) = 0.62
Contact your GP, study team, or supervising clinician if fatigue: Is severe enough to significantly impair daily functioning, work, or personal care Persists without any improvement despite the dose stabilising Is accompanied by dizziness, fainting, or palpitations , which may suggest dehydration or electrolyte disturbance Occurs alongside unexplained weight loss beyond expected levels , pallor, or breathlessness which could indicate nutritional anaemia Is associated with low mood, persistent sadness, or loss of motivation , as these may suggest depression rather than drug-related tiredness Develops alongside jaundice, dark urine, or abdominal pain , which warrant urgent assessment to exclude hepatic or pancreatic causes Seek urgent medical attention (call 999 or go to A&E) if you experience: Severe, persistent upper abdominal pain, particularly if it radiates to the back and is accompanied by vomiting these are potential symptoms of pancreatitis and require immediate assessment [12] Chest pain, severe dizziness, confusion, or an inability to keep any fluids down For urgent advice that does not require emergency services , contact NHS 111 (online at 111.nhs.uk or by telephone)
There is currently no approved pharmacy or prescription pathway for retatrutide anywhere in the world, so all access remains strictly research use only
